LIDDS
Uppsala
About LIDDS
LIDDS AB (publ) develops injectable drugs for cancer and other diseases based on our unique proprietary NanoZolid® technology. NanoZolid® helps solve some of the main problems with the way drugs work in the body and which affect patient quality of life. NanoZolid® enables the controlled, long-term and personalized release of drugs for up to six months. NanoZolid® can be combined with traditional small molecules as well as with larger molecules.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $4.4M
- Last round: Convertible Note (Feb 2022)
- Website: liddspharma.com
- Phone: +46 00 44 55 66
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/lidds-149623 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.